ABSTRACT
INTRODUCTION
Large-for-gestational age (LGA) is defined as an infant with a birth weight greater than the 90 th percentile for the given week of pregnancy.
LGA infants are at higher risk of morbidity, including shoulder dystocia and brachial plexus injury 1 , as well as mortality, including both antepartum stillbirth and delivery-related perinatal death 2 . Ultrasonographic fetal biometry can be used as a means of identifying suspected LGA fetuses. The two common candidate interventions following this diagnosis are planned Cesarean delivery, which may prevent the risk of birth injury, and early induction of labor, which may reduce birth weight by shortening the duration of pregnancy. A cost-benefit analysis indicated that Cesarean delivery for non-diabetic women with suspected macrosomia is not justified 3 . Until recently, there has been no direct evidence for a beneficial effect of induction of labor 4 ; however, a randomized controlled trial published in 2015 suggested that early induction of labor (between 37 + 0 and 38 + 6 weeks' gestation) for ultrasonically suspected LGA reduced a composite of shoulder dystocia and perinatal morbidity by about 70% without increasing the risk of Cesarean section 5 .
Currently, clinical guidelines in the UK and the USA recommend that women should not be screened routinely using ultrasound in the last third of pregnancy, as there is no clear evidence of benefit according to a meta-analysis of randomized controlled trials, and false-positive ultrasound diagnoses have the potential to cause harm through unnecessary interventions [6] [7] [8] . However, the UK guidelines recommended further research on the diagnostic effectiveness of universal ultrasound. We undertook a prospective cohort study between 2008 and 2013, designed to generate level-1 evidence of the diagnostic effectiveness of universal serial ultrasound (women and their carers were blinded to the results). We have reported previously our results on screening for fetal growth restriction 9 . The aims of the present study were to compare the diagnostic effectiveness of selective vs universal ultrasound as a screening test for LGA, and to determine which, if any, of a series of previously described ultrasound markers of excessive fetal growth could identify LGA fetuses at increased risk of adverse neonatal outcome.
METHODS

Study design
The Pregnancy Outcome Prediction study was a prospective cohort study conducted at the Rosie Hospital in Cambridge, UK, and has been described in detail previously 9, 10 . In brief, nulliparous women with a viable singleton pregnancy attending for their dating ultrasound scan between 14 January 2008 and 31 July 2012 were eligible for inclusion. Women who agreed to participate signed a consent form and were given follow-up appointments at approximately 20, 28 and 36 weeks' gestation at the UK National Institute for Health Research Cambridge Clinical Research Facility. Women were selected for clinically indicated ultrasound scans in the third trimester as per routine clinical care, using local and national guidelines, and the results of these scans were reported ('selective ultrasonography'). In addition, all women in the cohort underwent research ultrasound scans at 28 and 36 weeks, for which both the women and their clinicians were blinded to the results ('universal ultrasonography'). The study was designed to generate level-1 evidence of diagnostic effectiveness, as defined by the UK National Institute of Health and Care Excellence 11 . Inclusion criteria for the study were women who attended the 36-week research scan and had a live birth at the Rosie Hospital. Women who delivered before their 36-week scan appointment and those with missing biometric measurements were excluded. Reporting of this study conforms to the STARD (Standards for Reporting Diagnostic accuracy studies) guidelines 12 . Ethical approval for the study was obtained from the Cambridgeshire 2 Research Ethics Committee (reference number 07/H0308/163).
Selective and universal ultrasonography
Results of the clinically indicated scans were ascertained by linkage of the research data to the hospital's electronic ultrasonography database (Astraia, Munich, Germany). In both selective (clinically indicated) and universal (research) ultrasonography, fetal biometry included measurement of biparietal diameter (BPD), head circumference (HC), abdominal circumference (AC) and femur length (FL) using standard techniques. Estimated fetal weight (EFW) percentile was calculated using the Hadlock equations and reference standard 13, 14 . In cases in which all four measurements were available, the following formula employing all measurements was used: EFW = 10 (1.3596 -(0.00386×AC×FL) + (0.0064×HC) + (0.00061×BPD×AC) + (0.0424×AC) + (0.174×FL)) . If the head measurements were missing, the following formula based on AC and FL was used: EFW = 10 (1.304 + (0.05281×AC) + (0.1938×FL) -(0.004×AC×FL)) . Following delivery, the results of the research scans were unmasked and their associations with outcome were assessed.
Screening status in relation to EFW was classified on the basis of the last scan before giving birth (the 36-week scan for universal ultrasonography). For both selective and universal ultrasonography, screen positive was defined as EFW > 90 th percentile using an externally derived reference range and screen negative was defined as EFW ≤ 90 th percentile 13, 14 . Additionally, for selective ultrasonography, screen negative was defined as cases that did not have a clinically indicated scan at or after 34 weeks. Customized percentiles of EFW were also calculated based on published methods but employing coefficients from the latest model of Gestation-Related Optimal Weight (GROW v. 6.7.3_13 (UK), Gestation Network (www.gestation.net)) 15 . The associations between population-based and customized EFW > 90 th percentile and neonatal morbidity were compared.
Analysis of ultrasound indicators of overgrowth was performed by comparison of the association between EFW > 90 th percentile and neonatal morbidity in the presence or absence of the given factor. HC:AC and AC:FL ratios were classified according to the last measurement performed before birth. All measurements were quantified as gestational-age adjusted Z-scores, to account for variation in the exact timing of the ultrasound scans (Supplementary Tables 1 and 2 in Sovio et al. 9 ). AC growth velocity (ACGV) was quantified as the difference in AC Z-score between the 36-week and the 20-week scans. For these three indices (i.e. HC:AC ratio, AC:FL ratio and ACGV), deciles were generated using the distribution within the study cohort. The lowest decile of HC:AC and the highest deciles of AC:FL and ACGV were defined as abnormal. We also used classifications based on EFW > 80 th percentile and on ACGV > 1 SD in a sensitivity analysis. No other growth indices were studied to reduce the possibility of chance findings due to repeated hypothesis tests.
Outcome data
The outcomes of the pregnancies were ascertained by individual review of all paper records by research midwives, and by linkage of the research data to the hospital's electronic databases of delivery (Protos, iSoft, Banbury, UK), biochemical tests (Meditech, Westwood, MA, USA) and neonatal intensive care (Badgernet, Clevermed Ltd, Edinburgh, UK). The gold standard for LGA was birth weight > 90 th percentile for sex and gestational age, calculated using a UK reference 16 . Macrosomia was defined as birth weight > 4000 g, and severe macrosomia as birth weight > 4500 g. Neonatal morbidity was defined as one or more of the following criteria: 5-min Apgar score < 7, delivery with metabolic acidosis (defined as cord blood pH < 7.1 and a base deficit of > 10 mmol/L) or admission to the neonatal unit (i.e. neonatal intensive care unit, high-dependency unit or special care baby unit) at term (defined as admission < 48 h after birth at ≥ 37 weeks' gestation and discharge ≥ 48 h after admission). Severe adverse neonatal outcome was defined as live birth at term associated with neonatal death, hypoxic ischemic encephalopathy, use of inotropes, need for mechanical ventilation or severe metabolic acidosis (defined as cord blood pH < 7.0 and a base deficit of > 12 mmol/L). Shoulder dystocia and neonatal hypoglycemia were documented in the electronic delivery record. Additional cases of diagnosed hypoglycemia were obtained from the neonatal intensive care database, which was also used to identify cases of neonatal jaundice. These conditions were subclassified on the basis of whether they were associated with neonatal morbidity or severe adverse neonatal outcome, as defined above.
Statistical analysis
Continuous variables were compared using a two-sample Wilcoxon rank-sum test and categorical variables were compared using Pearson's chi-square test (with a trend test where appropriate) or Fisher's exact test if numbers were small. Sensitivity and specificity were compared using McNemar's test, positive and negative predictive values were compared using weighted generalized score tests 17 , and likelihood ratios were compared using regression model-based tests 18 . Analyses were repeated, adjusting for pre-existing diabetes and gestational diabetes using exact logistic regression. Interactions between EFW and ultrasound markers of overgrowth and their associations with neonatal morbidity were tested using the Mantel-Haenszel test or exact logistic regression, as appropriate. The conditional probabilities test was used to calculate P-values from the exact logistic regression, since the exact probabilities are analogous to the exact P-values obtained using Fisher's exact test 19, 20 . Statistical significance was set at P < 0.05 (two-sided) for main effects, and P < 0.10 for interactions. Statistical analysis was performed using Stata version 14.1 (StataCorp, College Station, TX, USA) and R version 3.0.2 (R Foundation for Statistical Computing, Vienna, Austria).
RESULTS
In total, 4512 women were recruited to the study and provided written informed consent 9 . Women who withdrew from the study or defaulted from their 36-week research scan (n = 326), and those who delivered before the 36-week scan (n = 176) or had missing biometric measurements (n = 12) were excluded. A further 127 women who were lost to follow-up or did not deliver at the Rosie Hospital and five women who had a stillbirth after their 36-week scan were also excluded ( Figure 1 ). The study group for the present analysis consisted of 3866 (86% of all recruited) women. Of these, 1354 (35%) women had a clinically indicated (selective) scan, including fetal biometry, at ≥ 34 weeks (Table 1) . Women having clinically indicated scans were more likely to be at the extremes of maternal age, to have discontinued education earlier in life, have a BMI > 30 kg/m 2 , have a history of miscarriage and to have pre-existing diabetes or to develop gestational diabetes, compared with the women who did not have clinically indicated scans. The average birth weight of the infants of women with clinically indicated scans was lower, and they had a greater proportion of LGA infants, birth before 40 weeks' gestation, induced labor and prelabor Cesarean delivery, compared with those who did not require a clinically indicated scan.
A total of 177 (4.6%) infants had a birth weight > 90 th percentile. The last clinically indicated (selective) scan before birth recorded an EFW > 90 th percentile in 47 of these cases, yielding a sensitivity of 27% (47/177). The research (universal) 36-week ultrasound scan recorded an EFW > 90 th percentile in 67 of these cases, yielding a sensitivity of 38% (67/177). The specificity was high for both approaches, but was slightly higher for selective compared with universal ultrasonography (99% vs 97%, respectively). The screening performance of universal vs selective ultrasonography for the prediction of LGA is presented in Table 2 . The area under the receiver-operating characteristics curve (AUC) for LGA detected by selective ultrasonography was 0.72 and the AUC for that by universal ultrasonography was 0.87 (P < 0.0001) ( Figure 2 ).
There was no evidence for an association between EFW > 90 th percentile on universal ultrasound and the risk of neonatal morbidity using either population-based or customized reference percentiles (Tables 3 and S1 ). The association between EFW > 90 th percentile and risk of neonatal morbidity was then assessed in relation to the three previously described indices of overgrowth, i.e. HC:AC and AC:FL ratios and ACGV (Figure 3) . Interaction with EFW > 90 th percentile was observed only for increased (i.e. top decile) ACGV, for both any morbidity (P = 0.08) and for severe adverse neonatal outcome (P = 0.03). There was no clear indication of an increased overall risk of adverse neonatal outcome when EFW was > 90 th percentile and ACGV was not in the top decile, unless the baby was LGA at birth (Table 3) . However, in cases in which universal ultrasonography indicated a LGA fetus with increased ACGV, the risk of any neonatal morbidity doubled (relative risk 2.0 (95% CI, 1.1-3.6); P = 0.04) and there was a greater than six-fold increased risk of severe adverse neonatal outcome (relative risk 6.5 (95% CI, 2.0-21.1); P = 0.01). When the outcome was confined to cases of neonatal morbidity in which the baby was confirmed to be LGA, ultrasound
LGA was associated with a 10-fold increased risk and 2007 , which is based on census data from area of mother's postcode. BMI, body mass index; BW, birth weight; DM, diabetes mellitus; GA, gestational age. 
Figure 2
Receiver-operating characteristics (ROC) curves for prediction of large-for-gestational-age neonate by estimated fetal weight (EFW) measured by selective ultrasonography at ≥ 34 weeks' gestation ( ) and by universal ultrasonography at 36-week research scan ( ). When results of selective ultrasonography were analyzed, 65% (2512/3866) of women did not have clinically indicated scan at ≥ 34 weeks. In this group, EFW centile was imputed using sex-specific population median (46.30 in males, 38.93 in females). Areas under ROC curves were 0.72 (95% CI, 0.68-0.76) for selective and 0.87 (95% CI, 0.85-0.90) for universal ultrasonography (P < 0.0001).
the combination of LGA and top decile of ACGV was associated with a greater than 20-fold increased risk. The associations remained very similar after adjustment for pre-existing diabetes and gestational diabetes (Table 3 ).
All analyses of ACGV were repeated using AC growth charts generated by the Fetal Growth Longitudinal Study component of the INTERGROWTH-21st Project 21 , and the associations were virtually unchanged (Table S2) . None of the indices of overgrowth was associated with adverse outcome when EFW was ≤ 90 th percentile (Table S3 ). The screening performance of universal ultrasonography for detecting macrosomia and severe macrosomia is presented in Table S4 . The AUC for macrosomia was 0.83 (95% CI, 0.81-0.85) and that for severe macrosomia was 0.87 (95% CI, 0.82-0.91). Of infants with EFW > 90 th percentile on universal ultrasound, 41% were delivered through intrapartum emergency Cesarean section, whereas the incidence was 17% for those with EFW ≤ 90 th percentile (risk ratio 2.50 (95%CI, 2.08-3.00)). Finally, there were no significant associations between suspicion of LGA on ultrasound, with or without increased ACGV, and the risk of shoulder dystocia ( Table 4 ). The risk of neonatal hypoglycemia was elevated when there was a combination of ultrasound suspicion of LGA and increased ACGV (Table S5 ) but the risk of jaundice was not elevated in any of the groups (Table S6) .
DISCUSSION
The main findings of this study are that universal ultrasonography increased the detection rate of LGA infants from 27% to 38%, and that the only ultrasound marker of fetal overgrowth that discriminated between LGA infants at increased risk for neonatal complications was ACGV.
LGA fetuses with normal ACGV were not at increased risk for adverse outcome; however, LGA fetuses with accelerated ACGV were at increased risk of adverse neonatal outcome, including severe adverse outcome.
This study has immediate implications for obstetric care. Many women have an ultrasound assessment in late pregnancy owing to indications that include prior risk factors and acquired pregnancy complications.
LGA will be diagnosed in a proportion of these women. This study indicates that, if such a diagnosis is made, assessment of ACGV would help assess the risk of associated complications. Diagnosis of LGA with normal ACGV did not appear to be associated with an increased risk of adverse neonatal outcome, whereas diagnosis of LGA with accelerated ACGV was significantly associated with an increased risk of any neonatal morbidity. This diagnostic combination was also significantly associated with severe adverse neonatal outcome but, as the latter occurred in only 0.6% of all infants, the association has relatively wide CIs (Figure 3b) . Importantly, we used AC measurement at the routine 20-week anomaly scan as the Customised Weight Centile Calculator (version 6.7 (UK)). ¶ACGV is based on change in gestational-age-adjusted Z-score between 20-week and 36-week scans; Z-score cut-off point of highest decile of ACGV is 1.4285. **Adjusted for pre-existing diabetes mellitus (DM) and gestational diabetes mellitus (GDM). † †Exposed cases n = 0, therefore 95% CI for RR not defined.
baseline measurement. This means that an assessment of growth velocity can be made even when a woman has had only a single scan in late pregnancy. Since the study aimed at assessing the diagnostic effectiveness of late pregnancy scanning, we excluded women who delivered before having their research scan at around 36 weeks' gestation. An interesting finding, which was also noted in our previous study on universal screening for small-for-gestational-age infants 9 , was that the positive likelihood ratio for LGA was significantly higher in the selective-screening group. We believe that this result probably reflects both the indication for the scan and the scan result itself, whereas the likelihood ratio from the universal screening reflects simply the scan result. Interestingly, the association between an ultrasound diagnosis of fetal overgrowth and neonatal morbidity was not mediated through an association with shoulder dystocia.
LGA, with or without increased ACGV, was not significantly associated with shoulder dystocia, whether considering any documentation of the condition at the time of delivery or shoulder dystocia associated with neonatal morbidity. Therefore, the association between fetal overgrowth and adverse neonatal outcome was mediated by other causes. This is consistent with the view that macrosomia associated with pathological fetal overgrowth has multiple adverse effects on the fetus, in addition to predisposing to birth injuries 22 . Serious shoulder dystocia (that accompanied by neonatal morbidity) affected only 1.6 per 1000 pregnancies in the current study, thus this analysis was underpowered to address this outcome. A recent randomized controlled trial demonstrated improved outcome following induction of labor at 37-38 weeks' gestation for suspected macrosomia 5 . That study employed women who had ultrasound scans for clinically suspected macrosomia and used an EFW threshold of > 95 th percentile, features that may explain the high rates of shoulder dystocia and severe morbidity. However, the current study demonstrates that these findings should be applied with caution to women who are suspected of having a LGA fetus in the absence of clinically suspected macrosomia, and that macrosomia may be associated with adverse neonatal outcome through mechanisms other than shoulder dystocia. Our findings are also consistent with those of a preliminary report from another prospective cohort study assessing blinded ultrasound EFW in nulliparous women, which showed no association with shoulder dystocia 23 . Finally, this study was underpowered to address the association between LGA and specific neonatal outcomes such as metabolic acidosis or low Apgar score, as these were present in < 1% of the cohort.
We found no evidence to suggest that the use of a customized EFW resulted in a stronger association between LGA and adverse neonatal outcome, although the present study was underpowered to address serious shoulder dystocia as an outcome. The aim of ultrasound assessment of growth is to differentiate pathological from healthy LGA. Customization of EFW attempts to achieve this by correcting estimated fetal size for maternal characteristics. Assessment of ACGV uses fetal AC in earlier pregnancy as the reference for later measurements, rather than using a reference modified for maternal characteristics. The highest decile was used to describe abnormal growth velocity since it is easy to use and interpret. The disadvantages are that it is specific to our cohort in its use of data-driven cut-off points and, similarly to any categorization of a continuous trait, assumes an unrealistic step function of risk and within-group homogeneity 24 . In both the current analysis and our previous analysis of SGA and fetal growth restriction, we found that ACGV was better than customization in identifying fetuses at the extremes of the distribution of EFW that were at increased risk for neonatal complications. However, we did find that the estimated association between customized EFW and shoulder dystocia was stronger, although statistically non-significant. In that case, the outcome is determined by the interaction between the size of the fetus and the size of the mother, and it is plausible that customization might perform better in that situation. We also used the INTERGROWTH-21st Project reference centiles, which performed similarly to population and customized centiles.
In conclusion, the present study found that universal third-trimester ultrasonographic fetal biometry increases the detection rate of LGA infants and, combined with ACGV, it can identify infants that are at increased risk of adverse neonatal outcome. The immediate clinical implication of the study is that, once a fetus is diagnosed as LGA, assessment of ACGV gives further information on the risk of associated complications, which helps to plan obstetric care in late pregnancy. The current study is also the first to provide level-1 evidence of the diagnostic effectiveness of universal ultrasound for detecting LGA. However, a randomized controlled trial would be required before clinical implementation of screening and intervention.
SUPPORTING INFORMATION ON THE INTERNET
The following supporting information may be found in the online version of this article: st reference centiles and perinatal outcome in study cohort (n = 3866) Table S3 Association between indicators of fetal abdominal overgrowth and perinatal outcome in neonates that were not diagnosed as large-for-gestational age (LGA) (n = 3689) Table S4 Diagnostic performance of universal ultrasonography for detection of infants with macrosomia Table S5 Association between estimated fetal weight (EFW), abdominal circumference growth velocity (ACGV) and neonatal hypoglycemia based on measurements on universal ultrasonography (n = 3866)
Table S6
Association between estimated fetal weight (EFW), abdominal circumference growth velocity (ACGV) and neonatal jaundice based on measurements on universal ultrasonography (n = 3866)
